Pembrolizumab showed a strong objective response in patients with metastatic or recurrent gastric cancer in the KEYNOTE-059 study, especially those whose PD-L1 combined positive score (CPS) was 1 or higher [5]. The gene discussed is CD274; the disease is gastric cancer.